{
  "Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis- Two Case Reports.pdf": {
    "processed_time": "20251214_142903",
    "status": "completed"
  },
  "yasuda-A phase I:II study of osimertinib in EGFR exon 20.pdf": {
    "processed_time": "20251214_142904",
    "status": "completed"
  },
  "Cardiac Toxicity Associated with Immune Checkpoint Inhibitors- Case Series and Review of the Literature.pdf": {
    "processed_time": "20251214_142906",
    "status": "completed"
  },
  "Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis a case series and systematic review.pdf": {
    "processed_time": "20251214_142904",
    "status": "completed"
  },
  "Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma.pdf": {
    "processed_time": "20251214_142915",
    "status": "completed"
  },
  "Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis A Comparative Analysis of Corticosteroid and Tofacitinib Treatment.pdf": {
    "processed_time": "20251214_142915",
    "status": "completed"
  },
  "A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.pdf": {
    "processed_time": "20251214_142917",
    "status": "completed"
  },
  "Case Series of Ventricular Tachycardia and Myocarditis From Programmed Cell-Death Protein-1 Inhibitor Treated With Infliximab.pdf": {
    "processed_time": "20251214_142917",
    "status": "completed"
  },
  "Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review.pdf": {
    "processed_time": "20251214_142915",
    "status": "completed"
  },
  "Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1:CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.pdf": {
    "processed_time": "20251214_142913",
    "status": "completed"
  },
  "Yamaguchi-A Phase II Study of Osimertinib .pdf": {
    "processed_time": "20251214_142916",
    "status": "completed"
  },
  "From Bad to Worse- The Clinical Spectrum of Immune Checkpoint Inhibitor Myocarditis and Associated 3M Syndrome with Concomitant Myositis and Myasthenia.pdf": {
    "processed_time": "20251214_142903",
    "status": "completed"
  },
  "Associated Myocarditis- A Predictive Factor for Response?.pdf": {
    "processed_time": "20251214_142917",
    "status": "completed"
  },
  "Fulminant myocarditis with combination immune checkpoint blockade  .pdf": {
    "processed_time": "20251214_142923",
    "status": "completed"
  },
  "Beyond T cell toxicity – Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition A two-case series and literature review.pdf": {
    "processed_time": "20251214_142917",
    "status": "completed"
  },
  "Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor-Related Myocarditis.pdf": {
    "processed_time": "20251214_142914",
    "status": "completed"
  },
  "信迪利单抗引发心脏生物标志异常的病例分析_韩兵.pdf": {
    "processed_time": "20251214_142923",
    "status": "completed"
  },
  "Bradyarrhythmias in Cardio-Oncology.pdf": {
    "processed_time": "20251214_142923",
    "status": "completed"
  },
  "使用特瑞普利单抗后新发三度房室传导阻滞2例_何花.pdf": {
    "processed_time": "20251214_142915",
    "status": "completed"
  },
  "Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.pdf": {
    "processed_time": "20251214_142915",
    "status": "completed"
  },
  "Checkpoint inhibitor-related myasthenia-myocarditis-myositis overlap syndrome in the orbit.pdf": {
    "processed_time": "20251214_142917",
    "status": "completed"
  },
  "Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.pdf": {
    "processed_time": "20251214_142903",
    "status": "completed"
  },
  "Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity  A single-center experience.pdf": {
    "processed_time": "20251214_142905",
    "status": "completed"
  },
  "Fatal Toxicity Induced by anti-PD-1 Immune Checkpoint Inhibitor in Thymic Epithelial Tumor.pdf": {
    "processed_time": "20251214_142907",
    "status": "completed"
  },
  "免疫检查点抑制剂治疗恶性肿瘤导致神经肌肉和心肌损害2例报告_陈嘉欣.pdf": {
    "processed_time": "20251214_142902",
    "status": "completed"
  },
  "程序性死亡受体1抑制剂致免疫相关性心肌炎的临床特征分析_廖音.pdf": {
    "processed_time": "20251214_142904",
    "status": "completed"
  },
  "A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.pdf": {
    "processed_time": "20251214_142904",
    "status": "completed"
  },
  "应用抗PD-1抗体治疗恶性淋巴瘤致少见不良反应的临床报告_姜利军.pdf": {
    "processed_time": "20251214_142903",
    "status": "completed"
  },
  "免疫检查点抑制剂致心肌炎合并肌炎和（或）重症肌无力重叠综合征老年患者的临床特征_王红梅.pdf": {
    "processed_time": "20251214_142904",
    "status": "completed"
  },
  "Case Report  Cardiac Toxicity Associated With Immune Checkpoint Inhibitors.pdf": {
    "processed_time": "20251214_142905",
    "status": "completed"
  },
  "Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis.pdf": {
    "processed_time": "20251214_142905",
    "status": "completed"
  },
  "无症状性免疫检查点抑制剂相关性心肌炎：案例及文献回顾_杨丽瑶.pdf": {
    "processed_time": "20251214_142905",
    "status": "completed"
  }
}